Levamisole

"Levamisole" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6)

Descriptor ID	D007978
MeSH Number(s)	D02.886.675.346 D03.383.129.308.480 D03.383.129.708.346
Concept/Terms	Levamisole Levamisole L-Tetramisole Levotetramisole Levamisole Hydrochloride Levamisole Hydrochloride Hydrochloride, Levamisole Solaskil Solaskil Dekaris Dekaris Decaris

Below are MeSH descriptors whose meaning is more general than "Levamisole".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Sulfur Compounds [D02.886]
Thiazoles [D02.886.675]
Levamisole [D02.886.675.346]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Azoles [D03.383.129]
Imidazoles [D03.383.129.308]
Levamisole [D03.383.129.308.480]
Thiazoles [D03.383.129.708]
Levamisole [D03.383.129.708.346]

Below are MeSH descriptors whose meaning is related to "Levamisole".

Below are MeSH descriptors whose meaning is more specific than "Levamisole".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Levamisole" by people in this website by year, and whether "Levamisole" was a major or minor topic of these publications.

Bar chart showing 14 publications over 10 distinct years, with a maximum of 3 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	0	2	2
2005	0	1	1
2009	0	1	1
2011	0	1	1
2012	0	1	1
2015	1	0	1
2017	1	0	1
2018	0	1	1
2021	1	1	2
2022	1	2	3

Below are the most recent publications written about "Levamisole" by people in Profiles.

Di Trana A, Berardinelli D, Montanari E, Berretta P, Basile G, Huestis MA, Busard? FP. Molecular Insights and Clinical Outcomes of Drugs of Abuse Adulteration: New Trends and New Psychoactive Substances. Int J Mol Sci. 2022 Nov 23; 23(23).

View in: PubMed
Nelson BN, Strathmann FG, Browne T, Cervantes A, Logan BK. Qualitative LC-Q-TOF Analysis of Umbilical Cord Tissue via Data-Dependent Acquisition as an Indicator of In Utero Exposure to Toxic Adulterating Substances. J Anal Toxicol. 2022 Jul 14; 46(6):619-624.

View in: PubMed
Calello DP, Aldy K, Jefri M, Nguyen TT, Krotulski A, Logan B, Brent J, Wax P, Walton S, Manini AF. Identification of a novel opioid, N-piperidinyl etonitazene (etonitazepipne), in patients with suspected opioid overdose. Clin Toxicol (Phila). 2022 09; 60(9):1067-1069.

View in: PubMed
Midthun KM, Nelson LS, Logan BK. Levamisole-a Toxic Adulterant in Illicit Drug Preparations: a Review. Ther Drug Monit. 2021 04 01; 43(2):221-228.

View in: PubMed
Ahmed ST, Nuni O, Tirumanisetty P, Zhao Y, Alhasson H, Mubasher M, Alweis R. Skin Necrosis Caused by Levamisole-Adulterated Cocaine. Am J Ther. 2021 Mar-Apr 01; 28(2):e263-e265.

View in: PubMed
Fiorentin TR, Krotulski AJ, Martin DM, Browne T, Triplett J, Conti T, Logan BK. Detection of Cutting Agents in Drug-Positive Seized Exhibits within the United States. J Forensic Sci. 2019 May; 64(3):888-896.

View in: PubMed
Ramesh S, Sobti D, Mancini R. Eyelid Necrosis and Secondary Cicatrical Ectropion Secondary to Levamisole-Associated Vasculitis. Ophthalmic Plast Reconstr Surg. 2017 May/Jun; 33(3S Suppl 1):S38-S40.

View in: PubMed
Patnaik S, Balderia P, Vanchhawng L, Markazi P, Wykretowicz J, Perloff S. Is Levamisole-Induced Vasculitis a Relegated Diagnostic Possibility? A Case Report and Review of Literature. Am J Case Rep. 2015 Sep 25; 16:658-62.

View in: PubMed
Myklebust MP, Li Z, Tran TH, Rui H, Knudsen ES, Elsaleh H, Fluge ?, Vonen B, Myrvold HE, Leh S, Tveit KM, Pestell RG, Dahl O. Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. Br J Cancer. 2012 Nov 06; 107(10):1684-91.

View in: PubMed
Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst. 2011 Oct 19; 103(20):1498-506.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement